Targeting drug-tolerant persister cells: Let's bring on the TROPs!

IF 56.1 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2026-07-13 Epub Date: 2026-06-18 DOI:10.1016/j.ccell.2026.05.019

Motohiro Izumi, Susumu S Kobayashi, Balazs Halmos

引用次数: 0

Abstract

In this issue of Cancer Cell, Liao et al. identify TROP2 as an EGFR tyrosine kinase inhibitor-induced vulnerability in drug-tolerant persister lung cancer cells. They show that anti-TROP2 antibody-drug conjugates target this residual population, supporting an "induce-target-kill" strategy to delay resistance and extend the benefit of EGFR tyrosine kinase inhibition.

查看原文本刊更多论文

靶向耐药持久性细胞：让我们使用trop ！

在这一期的Cancer Cell中，Liao等人发现TROP2是一种EGFR酪氨酸激酶抑制剂在耐药持久性肺癌细胞中诱导的易损性。他们表明，抗trop2抗体-药物偶联物靶向这些残留的群体，支持“诱导-靶向-杀伤”策略来延迟耐药性并延长EGFR酪氨酸激酶抑制的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.